X4 Pharmaceuticals, Inc
XFOR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XFOR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XFOR
X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with its approved product XOLREMDI and a lead pipeline candidate mavorixafor in Phase 3 for chronic neutropenic disorders.
Key risk: Capital need uncertainty
BioSniper Score
Based on 6 of 6 signals
Market Cap
$400.6M
Cash Runway
29.3 moLead Asset
xolremdi (Approved)
Next Catalyst
Phase3_Topline · Dec 30, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 18 clinical trials · 3 catalysts for X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with its approved product XOLREMDI and a lead pipeline candidate mavorixafor in Phase 3 for chronic neutropenic disorders.
- X4 Pharmaceuticals has one approved product, XOLREMDI, and is advancing mavorixafor in a Phase 3 trial for chronic neutropenic disorders [sec_mda · as of 2026-08-06].
- As of 2026-06-30, the company reported cash & equivalents of $195.8M, total revenue of $2.4M, and a net loss of $16.2M [sec].
- The company has incurred operating losses and expects to continue doing so as it advances its lead drug candidate through the 4WARD trial [sec_mda · as of 2026-08-06].
- X4 Pharmaceuticals has undergone strategic restructurings in February 2025 and September 2025 to reduce costs and focus resources [sec_mda · as of 2025-11-05].
- The company's funding requirements depend on multiple factors, including the progress and costs of its Phase 3 clinical trial for mavorixafor [sec_mda · as of 2026-08-06].
What works
- X4 Pharmaceuticals has an approved product, XOLREMDI, generating some revenue and providing a commercial foundation [sec_mda · as of 2025-11-05].
- The company has received FDA and European Commission designations such as Fast Track, Orphan Drug, and Breakthrough Therapy for its product candidates, which may facilitate development and regulatory review [sec · filed 2026-05-06].
- As of 2026-06-30, the company had $195.8M in cash and equivalents, providing a runway to fund operations for at least the next 12 months [sec] [sec_mda · as of 2026-03-17].
What to weigh
- X4 Pharmaceuticals has a history of operating losses and expects to continue incurring losses as it advances its pipeline, with a net loss of $16.2M for the quarter ended 2026-06-30 [sec] [sec_mda · as of 2026-08-06].
- The company will need to raise additional capital to fund operations beyond the current cash runway, and such funding cannot be assured [sec_mda · as of 2026-08-06].
- The company's Phase 3 trial for mavorixafor is a significant source of uncertainty, with costs and timelines that could materially affect funding requirements [sec_mda · as of 2026-08-06].
- X4 Pharmaceuticals has undergone multiple strategic restructurings, indicating ongoing challenges in aligning costs with revenue and pipeline progress [sec_mda · as of 2025-11-05].
From the filings
Quoted directly from source documents.
The company expects to continue incurring operating losses as it advances its lead drug candidate.
“to incur operating losses as we advance our lead drug candidate through the 4WARD trial.”
SEC MD&A · August 6, 2026
The company will need to raise additional capital to fund operations beyond the current period.
“Until we reach profitability, we will need to raise additional capital, which cannot be assured, to fund our operations and meet our financial obligations beyond this period.”
SEC MD&A · August 6, 2026
The company's funding requirements depend on the Phase 3 clinical trial of mavorixafor.
“the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates, particularly our Phase 3 clinical trial of mavorixafor for the treatment of individuals with chronic neutropenic disorders”
SEC MD&A · August 6, 2026
The company has received FDA and European Commission designations for its product candidates.
“the benefits of U.S. Food and Drug Administration (the "FDA") and European Commission designations, including, without limitation, Fast Track, Orphan Drug and Breakthrough Therapy”
SEC filings · May 6, 2026
Catalyst timeline
- 2026-12-30 · Phase3_Topline · sph4336 — Topline results from a Phase II/III study of SPH4336 in combination with endocrine therapy for HR-positive breast cancer; this is not X4 Pharmaceuticals' own pipeline candidate.
- 2027-11-01 · Phase3_Topline · mavorixafor — Topline results from the Phase 3 trial of mavorixafor in patients with chronic neutropenic disorders, a key value driver for the company.
- 2038-12-11 · Patent_Expiry · XOLREMDI — Patent/exclusivity expiry for XOLREMDI, which could affect long-term revenue from the approved product.
Risks & what to watch (4)›
Key risks
- Capital need uncertainty — The company will need to raise additional capital to fund operations beyond current cash runway, which cannot be assured [sec_mda · as of 2026-08-06].
- Phase 3 trial dependency
- History of operating losses — The company has incurred net losses and expects to continue doing so, with a net loss of $16.2M in the latest quarter [sec] [sec_mda · as of 2026-08-06].
- Restructuring execution risk — Multiple strategic restructurings in 2025 may indicate ongoing challenges in achieving profitability [sec_mda · as of 2025-11-05].
What to watch
- Phase 3 topline data for mavorixafor in chronic neutropenic disorders, expected around 2027-11-01 [upcoming catalysts].
- Cash burn rate and any additional financing activities, as the company will need to raise capital beyond its current runway [sec_mda · as of 2026-08-06].
- Commercial performance of XOLREMDI and its contribution to revenue [sec_mda · as of 2025-11-05].
- Updates on regulatory interactions and potential label expansions for XOLREMDI or mavorixafor [sec · filed 2026-05-06].
Sources: SEC filings · SEC MD&A · Generated August 19, 2026 · How we verify sources →
Run X4 Pharmaceuticals, Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available X4 Pharmaceuticals, Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
29.3 months
D/E 0.63 · 0% dilution
Lead: Approved
1 candidate
3 upcoming, next in ~122d
0 buys · 4 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
78
Total value held
$311.8M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 13,475,296 | $55.7M |
| morgan stanley | 9,466,992 | $39.1M |
| fmr llc | 8,103,400 | $33.5M |
| vanguard capital management llc | 6,995,224 | $28.9M |
| deep track capital, lp | 6,339,535 | $26.2M |
| braidwell lp | 3,272,954 | $13.5M |
| rosalind advisors, inc. | 3,214,766 | $13.3M |
| blackstone inc. | 2,681,922 | $11.1M |
| trails edge capital partners, lp | 2,571,478 | $10.6M |
| nantahala capital management, llc | 2,449,468 | $10.1M |
Showing top 10 of 78 institutional holders of X4 Pharmaceuticals, Inc. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.3%
- Days to cover
- 7.9
- Shares short
- 3,117,372
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XFOR short interestGovernance
Frequently asked questions
What is the AI investment thesis for X4 Pharmaceuticals, Inc?
X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with its approved product XOLREMDI and a lead pipeline candidate mavorixafor in Phase 3 for chronic neutropenic disorders.
What is X4 Pharmaceuticals, Inc's lead drug candidate?
X4 Pharmaceuticals, Inc's most advanced tracked candidate is xolremdi (Approved) for WHIM syndrome.
What is X4 Pharmaceuticals, Inc's next catalyst?
X4 Pharmaceuticals, Inc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positiv" — expected December 30, 2026.
Who is the CEO of X4 Pharmaceuticals, Inc?
Radius Health is the chief executive officer of X4 Pharmaceuticals, Inc (XFOR).
Where is X4 Pharmaceuticals, Inc headquartered?
X4 Pharmaceuticals, Inc (XFOR) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.